Journal of Thermal Analysis and Calorimetry

, Volume 115, Issue 3, pp 2479–2486 | Cite as

Investigation of the crystallinity of sugar alcohols co-ground with polymeric excipients

  • Csaba Mártha
  • Orsolya Jójárt-Laczkovich
  • Joachim Ulrich
  • Piroska Szabó-Révész
Article
First Online:
Received:
Accepted:

Abstract

Particle size reducing methods demand high energy input, so during these procedures crystallinity change always can occur. These changes can be enhanced by additives, which are often used to improve the dissolution, the powder rheological properties or the processability of the API (active pharmaceutical ingredient), or to support the particle size reduction. Different materials act differently during these crystallinity changing methods: some materials are easy to amorphize, while some of them can be really resistant. In this work, two chemically equivalent sugar alcohols as model materials—β-d-mannitol as poor glass former and d-sorbitol as good glass former—were chosen to be co-ground with polymeric additives (PVP C30 and PEG 6000). During the 120 min milling process mannitol showed just minor change in crystallinity alone or with PEG. But milled with PVP some amorphization was found. Sorbitol suffered noteworthy changes in crystallinity: raw sorbitol lost its crystallinity during the milling, and also polymorphic transition was displayed. Same transition happened during the milling with PVP: the whole crystallinity of the sorbitol decreased, while the amount of gamma polymorph increased. During the co-grinding with PEG, the polymer prevented the amorphization of sorbitol and kept the well-ordered crystal structure of the material.

Keywords

Mannitol Sorbitol Polyethylene glycol Polyvinylpyrrolidone Crystallinity Co-grinding 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgements

The work was supported by the European Union and cofunded by the European Social Fund (TÁMOP-4.2.2.A-11/1/KONV-2012-0035). The authors wish to acknowledge the cooperation supported by MÖB/DAAD. The help of Kati Bergt, Lydia Helmdach and Kristin Wendt with the XRPD and DSC measurements is gratefully acknowledged.

References

  1. 1.
    Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanoization strategies for poorly-water soluble drugs. Drug Discov Today. 2011;16:354–60.CrossRefGoogle Scholar
  2. 2.
    De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133–49.CrossRefGoogle Scholar
  3. 3.
    Kurti L, Kukovecz A, Kozma G, Ambrus R, Deli MA, Szabo-Revesz P. Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles. Powder Technol. 2011;212(1):210–7.CrossRefGoogle Scholar
  4. 4.
    Mallick S, Pattnaik S, Swain K, De PK, Saha A, Ghoshal G, Mondal A. Formation of physically stable amorphous phase of ibuprofen by solid state milling with kaolin. Eur J Pharm Biopharm. 2008;68:346–51.CrossRefGoogle Scholar
  5. 5.
    Sharma P, Denny WA, Garg S. Effect of wet milling process on the solid state of indomethacin and simvastatin. Int J Pharm. 2009;380:40–8.CrossRefGoogle Scholar
  6. 6.
    Brodka-Pfeiffer K, Langguth P, Grafi P, Hausler H. Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur J Pharm Biopharm. 2003;56:393–400.CrossRefGoogle Scholar
  7. 7.
    Yonemochi E, Kitahara S, Maeda S, Yamamura S, Oguchi T, Yamamoto K. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. Eur J Pharm Sci. 1999;7:331–8.CrossRefGoogle Scholar
  8. 8.
    Mártha C, Kürti L, Farkas G, Jójárt-Laczkovich O, Szalontai B, Glässer E, Deli MA, Szabó-Révész P. Effects of polymers on the crystallinity of nanonized meloxicam during a co-grinding process. Eur Polym J. 2013;49:2426–32.CrossRefGoogle Scholar
  9. 9.
    Lin SY, Hsu CH, Ke W. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int J Pharm. 2010;396:83–90.CrossRefGoogle Scholar
  10. 10.
    Chieng N, Rades T, Saville D. Formation and physical stability of the amorphous phase of ranitidine hydrochloride polymorphs prepared by cryo-milling. Eur J Pharm Biopharm. 2008;68:771–80.CrossRefGoogle Scholar
  11. 11.
    Yu S, Adams MJ, Gururajan G, Reynolds G, Roberts R, Wu CY. The effects of lubrication on roll compaction, ribbon milling and tableting. Chem Eng Sci. 2013;86:9–18.CrossRefGoogle Scholar
  12. 12.
    Arias MJ, Moyano JR, Gines JM. Investigation of the triamterene-β-cyclodextrin system prepared by co-grinding. Int J Pharm. 1997;153:181–9.CrossRefGoogle Scholar
  13. 13.
    Bettinetti G, Mura P, Faucci MT, Sorrenti M, Setti M. Interaction of naproxen with noncrystalline acetyl β- and acetyl γ-cyclodextrins in the solid and liquid state. Eur J Pharm Sci. 2002;15:21–9.CrossRefGoogle Scholar
  14. 14.
    Izutsu K, Yoshioka S, Terao T. Effect of mannitol crystallinity on the stabilization of enzymes during freeze-drying. Chem Pharm Bull. 1994;42:5–8.CrossRefGoogle Scholar
  15. 15.
    Kim AI, Akers MJ, Nail SL. The physical state of mannitol after freeze-drying: effects of mannitol concentration, freezing rate, and a noncrystallizing cosolute. J Pharm Sci. 1998;87:931–5.CrossRefGoogle Scholar
  16. 16.
    Maury M, Murphy K, Kumar S, Mauerer A, Lee G. Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur J Pharm Biopharm. 2005;59:251–61.CrossRefGoogle Scholar
  17. 17.
    Tee SK, Marriot C, Zeng XM, Martin GP. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm. 2000;208:111–23.CrossRefGoogle Scholar
  18. 18.
    Reitz E, Vervaet C, Neubert RHH, Thommes M. Solid crystal suspensions containing griseofulvin—preparation and bioavailability testing. Eur J Pharm Biopharm. 2013;83:193–202.CrossRefGoogle Scholar
  19. 19.
    Gombás Á, Szabó-Révész P, Regdon G Jr, Erős I. Study of thermal behaviour of sugar alcohols. J Therm Anal Calorim. 2003;73:615–21.CrossRefGoogle Scholar
  20. 20.
    Pomázi A, Ambrus R, Sipos P, Szabó-Révész P. Analysis of co-spray-dried meloxicam–mannitol systems containing crystalline microcomposites. J Pharm Biomed Anal. 2011;10/56(2):183–90.CrossRefGoogle Scholar
  21. 21.
    Hamishehkar H, Emami J, Najafabadi AR, Gilani K, Minaiyan M, Mahdavi H, Nokhodchi A. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm. 2010;15/389(1–2):74–85.CrossRefGoogle Scholar
  22. 22.
    Cavatur RK, Vemuri NM, Pyne A, Chrzan Z, Toledo-Velasquez D, Suryanarayanan R. Crystallization behavior of mannitol in frozen aqueous solutions. Pharm Res. 2002;19:6.CrossRefGoogle Scholar
  23. 23.
    Nezzal A, Aerts L, Verspaille M, Henderickx G, Redl A. Polymorphism of sorbitol. J Cryst Growth. 2009;311:3863–70.CrossRefGoogle Scholar
  24. 24.
    Martini A, Torricelli C, De Ponti R. Physico-pharmaceutical characteristics of steroid-crosslinked polyvinylpyrrolidone coground systems. Int J Pharm. 1991;75(2-3):141–6.CrossRefGoogle Scholar
  25. 25.
    Wu JZ, Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci. 2006;29(1):35–44.CrossRefGoogle Scholar
  26. 26.
    Mura P, Cirri M, Faucci MT, Ginès-Dorado JM, Bettinetti GP. Investigation of the effects of grinding and co-grinding on physicochemical properties of glisentide. J Pharm Biomed Anal. 2002;30(2):227–37.CrossRefGoogle Scholar
  27. 27.
    Ambrus R, Aigner Z, Catenacci L, Bettinetti G, Szabó-Révész P, Sorrenti M. Physico-chemical characterization and dissolution properties of nifluminic acid-cyclodextrin-PVP ternary systems. J Therm Anal Calorim. 2011;104:291–7.CrossRefGoogle Scholar
  28. 28.
    Yam N, Li X, Jasti BR. Interactions of topiramate with polyethylene glycol 8000 in solid state with formation of new polymorph. Int J Pharm. 2011;411(1-2):86–91.CrossRefGoogle Scholar
  29. 29.
    Bailey FE, Koleske JV. Poly(ethylene oxide). New York: Academic; 1976.Google Scholar
  30. 30.
    Craig DQM, Royall PG, Kett VL, Hopton ML. The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. Int J Pharm. 1999;179:179–207.CrossRefGoogle Scholar
  31. 31.
    Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48:27–42.CrossRefGoogle Scholar
  32. 32.
    Jójárt-Laczkovich O, Szabó-Révész P. Formulation of tablets containing an ‘in-process’ amorphized active pharmaceutical ingredient. Drug Dev Ind Pharm. 2011;37:1272–81.CrossRefGoogle Scholar
  33. 33.
    Uvarov V, Popov I. Development and metrological characterization of quantitative X-ray diffraction phase analysis for the mixtures of clopidogrel bisulphate polymorphs. J Pharm Biomed Anal. 2008;46:676–82.CrossRefGoogle Scholar
  34. 34.
    Tiwari M, Chawla G, Bansal AK. Quantification of olanzapine polymorphs using powder X-ray diffraction technique. J Pharm Biomed Anal. 2007;43:865–72.CrossRefGoogle Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2013

Authors and Affiliations

  • Csaba Mártha
    • 1
  • Orsolya Jójárt-Laczkovich
    • 1
  • Joachim Ulrich
    • 2
  • Piroska Szabó-Révész
    • 1
  1. 1.Department of Pharmaceutical TechnologyUniversity of SzegedSzegedHungary
  2. 2.Center for Engineering Science, Process TechnologyMartin Luther University Halle-WittenbergHalleGermany

Personalised recommendations